Drug Profile
ENERGI F701
Alternative Names: ENERGI-F701Latest Information Update: 10 Mar 2021
Price :
$50
*
At a glance
- Originator Energenesis Biomedical
- Class Skin disorder therapies
- Mechanism of Action AMP activated protein kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Alopecia
Most Recent Events
- 10 Mar 2021 Phase II development is still ongoing in Taiwan (Energenesis Biomedical pipeline, March 2021)
- 23 May 2018 Phase-II clinical trials in Alopecia in Taiwan (Topical) (NCT03351322)
- 22 Nov 2017 Energenesis Biomedical and A2 Healthcare Taiwan Corporation plan a phase II trial for Alopecia (Topical) (NCT03351322)